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Introduction
Necrotising enterocolitis (NEC) is the most common gastrointestinal 
disease in preterm neonates.1 The aetiology of NEC remains poorly 
understood. Proposed preventive strategies include the provision of 
breast milk as an enteral feed, monitoring the advancement of feeds 
and modulating the gut microbiome by providing probiotics.1,2
Some patients who present with NEC require surgical intervention 
for the resection of a necrotic bowel which may result in short bowel 
syndrome (SBS). SBS may also result from congenital defects or 
disease-associated loss of absorption, and is characterised by the 
inability to maintain protein, energy, fluid, electrolyte or micronutrient 
balance when on a conventionally accepted, normal diet.3 
The clinical course and nutritional management of a preterm infant 
with SBS is described in this case study. New developments in the 
prevention of NEC are briefly discussed. Relevant evidence with 
regard to nutritional management is reviewed, and practical aspects 
of the management discussed. 
Case study
A 25-year-old multigravida mother presented in spontaneous 
preterm labour. She was tocolysed to delay delivery, and received two 
intramuscular steroid injections. A male infant was born via normal 
vertex delivery at 29 weeks’ gestation. The Apgar (appearance, 
pulse, grimace, activity and respiration) scores documented at one 
and five minutes were 6 and 8, respectively. The infant presented 
with moderate respiratory distress, and required admission to the 
intensive care unit for continuous positive airway pressure (CPAP) 
support. On day 5 of life, the patient had neonatal jaundice, for which 
phototherapy was required, with the subsequent normalisation of 
total bilirubin levels. Phototherapy was stopped on day 7 of life. 
CPAP was stopped on day 2, and oxygen given via nasal cannula. 
Thereafter, on day 3 of life, he was weaned to room air. 
Anthropometry
The infant’s birthweight was 1 080g, which is classified as very low 
birthweight. His birth length was 37 cm and head circumference 
27 cm. These measurements were plotted on a gender-specific 
Fenton growth chart.4 All measurements were below the 50th centile 
for gestational age and showed proportional growth in utero. After 
initial weight loss post delivery (12% of his birthweight) due to 
adaption processes after birth, his weight increased by 14 g/kg/day. 
Management
The patient received donor-expressed breast milk and mother’s 
expressed breast milk via an orogastric tube. The mother received 
intensive breastfeeding support in the hospital. Feeds were 
introduced at 22 ml/kg on day 1 of life, and increased by 35 ml/
kg/day. Probiotics (Pro-B2®, C Pharm) (0.2 ml/day) were started 
on day 3 of life. Once the patient achieved a feed of 150 ml/kg, 
providing an estimate of 101 kcal/kg and 1.8 g protein/kg daily, a 
multinutrient breast milk fortifier (FM 85®, PreNAN) and multivitamin 
(Multi-Vitamin®, Pharmachem) (0.3 ml/day) were initiated, providing 
a combined total of 118 kcal/kg, and 2.8 g protein/kg daily. To ensure 
adequate nutritional intake and growth, feeds were incrementally 
increased to 200 ml/kg, providing an estimate of 146 kcal/kg and 
3.3 g protein/kg daily. No clinical signs of feeding intolerance were 
noted during the advancement of feeds. A preterm formula, which 
provided 136 kcal/kg and 4.02 g protein daily, was introduced on day 
15 of life due to an inadequate breast milk supply.
On day 21 of life, the infant presented with abdominal distension, 
bile-stained vomit and bloody stools. All feeds, probiotics and 
multivitamins were stopped. He developed respiratory failure 
and required intubation and ventilator support. He was started on 
inotropes for hypotension. An abdominal X-ray showed pneumatosis 
intestinalis, indicating NEC. C-reactive protein was increased 
(Table I), and the patient was commenced on antibiotic treatment 
(meropenem, 20 mg/kg). Parenteral nutrition (PN) was started via a 
peripherally inserted central catheter at 64 ml/kg, providing 45 kcal 
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and 1.3 g protein/kg daily, and sodium-containing intravenous (IV) 
fluids were given for hyponatraemia. The infant was transferred to 
another tertiary institution for surgical intervention. 
During surgery, resection of a short segment of proximal jejunum 
25 cm after the duodenojejunal flexure, and the terminal ileum and 
ileocaecal valve, was performed, as well as a total colectomy. Twenty-
five centimetres of jejunum proximal to the duodenojejunal flexure, 
and 27 cm of distal jejunum and ileum, were viable, providing a total 
of 52 cm of viable small bowel remaining. A primary jejunojejunal 
anastomosis was performed and an end-ileostomy fashioned.
Post surgery, the patient was intubated and required ventilator 
support. He presented with hypocalcaemia and hypokalaemia, 
which was treated with IV calcium gluconate (5 ml/kg/day) and 
potassium chloride (KCl) (0.2 mmol/kg/hour), titrated to normal 
levels. PN continued at 60 ml/kg, providing 43 kcal and 1.2 g 
protein/kg daily, and IV fluids at 40 ml/kg. Fluids were restricted to 
100 ml/kg because of mild oedema. Adrenaline (0.6 mg/kg/minute) 
was started postoperatively for hypovolaemia, and weaned on day 
3 postoperatively. The patient was thrombocytopaenic and received 
platelet transfusions.
The patient was kept nil per os for three days postoperatively owing 
to increased nasogastric aspirates. PN was continued at 60 ml/kg, 
and then increased to 80 ml/kg on day 3 postoperatively. Nasogastric 
feeds were started on day 3 post surgery at 1 ml/hour (20 ml/kg) of 
breast milk expressed by the mother. The oedema improved, and 
PN was increased to 100 ml/kg, providing 71 kcal/kg and 2.1 g 
protein/kg, on day 4. Magnesium sulphate (0.1 ml/kg) and KCl (0.2 
mmol/kg/hour), were supplemented as the blood levels were low 
on day 5 post surgery. Feeds were incrementally increased by 1 
ml/hour/day (18 ml/kg). A casein-dominant extensively hydrolysed 
formula was provided when the mother could not provide adequate 
breast milk. She received breastfeeding support at regular intervals 
at both institutions. On day 8 post surgery, PN was increased to 
120 ml/kg (85 kcal/kg and 2.5 g protein/kg). Enteral feeds were set at 
40 ml/kg, providing 27 kcal/kg and 0.7 g protein/kg daily. The patient 
was transferred back to the original facility. 
The enteral feeds were increased by 1 ml/hour/day (16 ml/kg) 
per day, and titrated against PN at a fluid volume of 160 ml/kg. 
Electrolyte-containing replacement fluid (100 ml of 0.45% normal 
saline with 1ml KCl) was given when the stoma losses were 
≥ 30 ml/kg. Stoma losses increased on day 15 postoperatively to 
80 ml/kg, and an amino acid-based formula was introduced. 
Loperamide (0.1 mg/kg) was given to reduce gut motility, and a 
proton-pump inhibitor (omeprazole) (0.5 mg/kg) prescribed to 
reduce gastric secretions. Poor growth was experienced, and the 
weight plateaued at 1 540 g. Losses remained high, and the enteral 
feeds were reduced to 16 ml/kg, with a subsequent decrease in 
ileostomy losses to ≤ 30 ml/kg.
The enteral feeds were again increased incrementally by 1 ml/hour/
day (16 ml/kg) when the stoma losses were ≤ 30 ml/kg. Small oral 
feeds of breast milk expressed by the mother, when available, were 
introduced for oral stimulation. Neonatal cholestasis and elevated 
liver enzymes were shown in routine PN blood samples on day 14 
postoperatively. As a PN regimen containing fish oil lipid emulsions 
was not routinely available at the institution, the pharmacy was 
tasked to procure these PN products. Ursodeoxycholic acid 
(20 mg/kg/day), a hydrophilic derivative of chenodeoxycholic acid, 
which acts by displacing toxic bile salts, was recommended.5 
On day 51 of life, the C-reactive protein and white blood cells 
were raised. Antibiotics (vancomycin 10 mg/kg, and meropenem 
20 mg/kg) were prescribed. Phosphate supplementation (1 mmol/
Table I: The blood values of the monitored variables during the course of treatment
Monitored variables Normal values Day 20 Day 21 Day 40 Day 51 Day 58
Sodium (mmol/l) 136–145 131 118 141 136 129
Potassium (mmol/l) 4.1–5.3 - 7.2 3.9 4.7 3.8
Urea (mmol/l) 0.7–4.6 - 5.0 1.0 1.5 2.5
Creatinine (µmol/l) 14–34 - 32 - 20 13
Magnesium (mmol/l) 0.66–1.03 - 1.07 0.87 0.97 0.82
Calcium (corrected) (mmol/l) 2.17–2.62 - 2.18 2.08 2.09 2.02
Phosphate (mmol/l) 1.15–2.15 2.14 2.39 1.44 0.85 1.35
Albumin (g/l) 28–46 - - - - 19
Total bilirubin (µmol/l) 5–21 - - 49 44 53
Conjugated bilirubin (µmol/l) 0–5 - - 46 48
Alkaline phosphatase (µmol/l) 82–383 - - - 777 822
Alanine transaminase (U/l) 4–35 367 10 6 11
Aspartate transaminase (U/l) 0–65 - - - 41 -
γ-glutamyl transferase (U/l) 12–122 - - 180 178 -
C-reactive protein (mg/l) ≤ 10 32 - 19 8
Haemoglobin (g/dl) 9.1–13.0 11.6 8.0 7.2 7.9
White cell count (x 109/l) 5.5–18.0 - - 13.26 194.80 11.26
Platelet count (x 109/l) 140–350 - - 217 177 159
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kg/day) for hypophosphataemia was started on day 21, and an oral 
multivitamin (0.3 ml, twice daily) started once 75% of the enteral 
feeds were tolerated. As the primary site of vitamin B12 absorption, 
i.e. the terminal ileum, had been resected, intramuscular vitamin 
B12 supplementation (20 µg) was recommended. PN and EN were 
titrated at 160–180 ml/kg, providing full nutritional requirements. 
Enteral feeds provided 75% of nutritional requirements on day 32 
postoperatively. The patient’s weight was 1 920 g, and he was 
gaining weight at 16 g/kg/day. The patient was referred back to a 
specialised paediatric centre for further management on day 32. 
By day 77 of life, the patient had received 60% of his requirements 
via the enteral route and 40% parenterally, and his weight has 
increased to 2.2 kg. 
Nutritional requirements
According to the European Society for Paediatric Gastroenterology 
Hepatology and Nutrition (ESPGHAN) guidelines, the enteral energy 
requirements for neonates is 110–135 kcal/kg, with protein 
requirements of 3.5-4.0 g protein/kg for very low-birthweight preterm 
neonates between 1 000 g and 1 800 g (Table II).6 The parenteral 
energy requirement is 10% less than the enteral requirement 
because of the contribution of dietary-induced thermogenesis. 
When nutrition is provided via the parenteral route, 110–120 kcal/
kg of energy, 3–4 g of lipids/kg, 1.5–4.0 g amino acids/kg and up to 
18 g/kg/day of carbohydrate, daily, are recommended.7 
A summary of the nutritional delivery for the course of treatment of 
this patient is summarised in Table III. Owing to the need for fluid 
restrictions post surgery, nutritional support for this patient was 
provided at 40–60% of his nutritional requirements. Thereafter, 
when the fluid restriction was lifted, full requirements were provided. 
However, his weight gain remained poor. The slower increase of 
enteral feeds based on tolerance, and titrating enteral nutrition and 
PN at a higher fluid volume, aided consistent growth thereafter. 
Discussion
Prevention of necrotising enterocolitis 
The advancement of enteral feeds has been studied as a modifiable 
risk factor for NEC. The slower advancement of feeds in daily 
increments of 15–24 ml/kg/day is common practice, and was 
previously thought to reduce the risk of NEC developing. The slower 
advancement of feeds was demonstrated to result in increased time 
to reach full feeds, as well as an increased risk of developing invasive 
infection, in a recent Cochrane review by Morgan et al.2 The absence 
of an increased risk of the development of NEC or death in very 
low-birthweight infants, associated with advances in increments of 
30–40 ml/kg, was also reported in this review. 
Mother’s own milk contains immunological properties which promote 
intestinal maturation and adaptation, improves feeding tolerance and 
Table III: Nutrient delivery to the patient during the course of treatment
Days post 
surgery 
PN EN Oral feeds Clinical aspects
1–3 PN provided at 60–80 ml/kg Nil per os • High gastric aspirates
• Fluid restriction due to oedema
• IV potassium and calcium
4–14 PN titrated against EN at  
100–150 ml/kg
Breast milk expressed by the mother 
and extensively hydrolysed formula
incrementally increased by 20 ml/kg to 
80 ml/kg
• Stoma losses of 15–33 ml/kg
• Insufficient volumes of breast milk 
expressed by the mother available
15 PN provided at 50 ml/kg Breast milk expressed by the mother 
and extensively hydrolysed formula 
provided at 100 ml/kg
• Stoma losses of 80 ml/kg
• Insufficient volumes of breast milk 
expressed by the mother available
16 PN provided at 50 ml/kg Amino-acid based formula at 100 ml/kg • Stoma losses of 87 ml/kg
• No breast milk available
• Poor growth
18 PN titrated against EN at  
160 ml/kg
Amino-acid based formula feeds 
reduced to 16 ml/kg
• Stoma losses reduced to ≤ 30 ml/kg
19–31 PN titrated against EN at  
160–180 ml/kg
Feeds of  amino-acid based formula 
and breast milk expressed by the 
mother increased by 16 ml/kg/day
Small oral feeds of 
breast milk expressed 
by the mother 
introduced
• Stoma losses of 10–25 ml/kg
• When losses of  ≥ 30 ml/kg were reached, 
the feed was not increased
• Satisfactory weight gain of 16 g/kg/day
EN: enteral nutrition, IV: intravenous, PN: parenteral nutrition





Energy (kcal/kg) 110–120 110–135
Protein (g/kg) 1.5–4.0 3.5–4.0
Carbohydrate (g/kg) 13–18 11.6–13.2
Fat (g/kg) 3–4 4.8–6.6
Na (mmol/kg) 3.5–5.0 3.0–5.0
K (mmol/kg) 2.5–5.0 1.7–3.4
Cl (mmol/kg) 2.0–3.0 3.0–5.0
Ca (mmol/kg) 1.5–2.0 3.0–3.5
P04 (mmol/kg) 1.5–1.9 1.9–2.9
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remains the first feed choice for preterm infants.6 When a mother’s 
milk is not available, the alternatives are either artificial formula or 
donor breast milk. Formula feeding is associated with superior short-
term growth rates, but increases the risk of NEC. Therefore, donor 
milk is used when breast milk is not available.8
The routine use of probiotics to prevent NEC remains controversial. 
While some strongly support the use of probiotics, others criticise 
the routine use thereof owing to the heterogeneity of pooled data 
and lack of data on long-term outcomes.9 There is a lack of data on 
adverse effects, especially in extremely low-birthweight (≤ 1 000 g) 
infants, and particular caution should be taken with respect to this 
group. More research is needed to establish effective preparations, 
the safety of various strains, timing and length of probiotic use.1 It is 
important to note that the benefits of probiotics are strain specific, 
and should be used according to the specific strain’s proven 
therapeutic effect. The ESPGHAN committee on nutrition advises 
that the safety and clinical effects of one product should not be 
extrapolated to others.10 Guidelines were published by Deshpande 
et al to address some of these concerns and to optimise the use of 
probiotic supplementation.9
An improvement in the prevention of severe NEC and a reduction in 
all-cause mortality in preterm infants in association with probiotic 
use was shown in a review of randomised or quasi-randomised 
controlled trials. The findings also strongly supported the change in 
clinical practice.1 The recommendation for probiotics was reviewed 
in a recent consensus paper. Probiotic strains, Lactobacillus 
acidophilus NCDO1748 and Bifidobacterium bifidium NCDO1453, 
received a grade B recommendation for the prevention of NEC.11 
The probiotic used in the current case consisted of 1 x 109 colony-
forming units of L. rhamnosus GG and B. infantis per day. This has 
been shown to reduce the incidence of NEC in very low-birthweight 
infants in a similar setting.12
Short bowel syndrome
The main aim of nutritional management of SBS post surgery is to 
facilitate gut adaption, ensure normal growth and development, and 
to prevent electrolyte imbalances.13 
Three phases of nutritional management after gastrointestinal 
resection are recognised.13 The first phase (acute phase) follows the 
recovery from postoperative ileus. This phase may last 1–3 weeks, 
and is characterised by gastric hypersecretion and large electrolyte 
and stoma fluid losses, for which PN and IV fluid replacement are 
required. The second phase (recovery phase) may last for weeks 
to months, and is characterised by an improvement in the stoma 
losses as the gut adapts. Enteral feeds are slowly increased and 
titrated against PN to ensure adequate nutritional intake during 
this period. Full enteral feeds are tolerated because of successful 
intestinal adaption during the third phase (maintenance phase). PN 
can potentially be discontinued during this phase.
The need for PN and IV fluid replacement depends on the length 
and quality of residual bowel, the remaining anatomy and the 
presence or absence of the ileocaecal valve.13 The duration of PN 
dependence in 63 neonates with a short bowel was investigated in 
a retrospective study. It was found that the mean duration of PN was 
4.8 months when the small bowel intestinal length was ≥ 50 cm, and 
33 months when the intestinal length was ≤ 50 cm.14 Ideally, these 
patients should be cared for within a specialised multidisciplinary 
team, consisting of paediatric surgeons, gastroenterologists, a 
dietician, and nurses and pharmacists with experience in intestinal 
failure. Outcomes have been demonstrated to improve following 
management of these patients by a multidisciplinary team.15
Choice of enteral feed
Breast milk remains the first choice as an enteral feed as it contains 
immune-enhancing properties, beneficial bacteria and growth 
factors. Breast milk is associated with good gastrointestinal tolerance 
and gut adaption, resulting in a shorter duration of PN dependence.16 
Currently, there is no consensus regarding which formula to use 
when breast milk is unavailable. Great variation in practice exists 
because of the lack of randomised controlled trails. An individualised 
approach may be necessary with respect to choosing an appropriate 
formula. When focusing on the goals of nutritional therapy in SBS, 
nutrients with the greatest potential for gut adaptation, such as 
whole proteins and long-chain fatty acids, should be considered 
initially. Protein is absorbed in the upper small bowel and is largely 
unaffected by NEC-associated gut resections. 
Extensively hydrolysed formula or amino acid-based formula can be 
introduced in a stepwise manner when intolerance to a polymeric feed 
is suspected. Medium-chain triglyceride-containing formulations 
may be beneficial when it becomes evident that fat absorption is 
compromised. A lactose-free feed should be used when transient 
lactose intolerance is evident. Cow’s milk protein intolerance and 
non-immunoglobulin E-mediated allergies have been reported in 
these infants. A protein hydrolysate may be appropriate in these 
cases. 
When to start enteral feeds
Enteral nutrition can be started as soon as possible after surgery. 
Early enteral feeding, i.e. 12 hours post surgery, has been associated 
with the earlier attainment of full enteral feeds.16 Continuous feeds 
are generally better tolerated than bolus feeds. Feeds delivered in a 
continuous fashion improve nutrient absorption and gut adaptation 
by providing optimum luminal exposure time.13
How to increase enteral feeds
There is a paucity of data on the optimal rate with regard to the 
increase in enteral feeds post surgery for SBS. Therefore, practices 
are mainly based on expert opinion. According to Vanderhoof and 
Young, enteral feeds can be slowly increased by 1 ml/hour/day, 
based on individual tolerance.17 Tolerance is assessed by volume 
and the consistency of the ostomy effluent, vomiting and the 
presence of faecal-reducing substances. Stool output limits are set 
on a surrogate threshold of 40–50 ml/kg.18 Because of high levels 
of electrolyte losses in the effluent (Table IV), which are dependent 
on the region of the ostomy, the patient may be at increased risk 
of electrolyte disturbances above this threshold. Higher ostomy 
output is accepted in some centres. However, frequent electrolyte 
monitoring is performed, and appropriate fluid and electrolyte 
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replacement given. Typically, we aim for a stomal output of 30 ml/
kg to prevent electrolyte imbalances. Enteral feeding is increased 
to tolerance, and the volume can be increased incrementally as the 
bowel adapts. 










Gastric 140 15 155
Ileostomy 80–140 15 115 40
Colostomy 50–80 10–30 40 20–25
Secretory 60–120
Diarrhoea 30–40 10–80 10–110 30
Normal stool 5 10 10 0
When to start oral feeds
Early oral feeding is recommended to stimulate the suck-swallow 
reflex and for oral motor development.16 Other benefits of oral feeds 
include increased gastrointestinal secretions of trophic factors and 
the release of salivary epidermal growth factor, which contributes 
to gut adaption and protects against PN-associated liver disease 
(PNALD).13
There is no evidence on the ideal time to start oral feeding.16 
Therefore, a pragmatic approach is used in our centre, i.e. providing 
small oral feeds, in addition to continuous gastric feeding, as soon as 
the patient is between 34 and 36 weeks’ gestation, clinically stable, 
not dependent on invasive respiratory support and shows readiness 
to feed. 
Parenteral nutrition-associated liver disease 
PNALD is a potentially life-threatening complication in children 
receiving long-term PN. Risk factors for PNALD include prematurity, 
sepsis, extensive gut resections, and bacterial overgrowth and/
or translocation, as well as lack of enteral stimulation.19 The exact 
aetiology of PNALD is unknown, but hepatotoxic factors, including 
the use of soy bean-based lipid emulsions, have been hypothesised 
as a likely cause. Fish oil-containing lipid emulsions have been 
investigated with respect to reversing neonatal cholestasis and liver 
dysfunction. A lipid emulsion containing soy beans, medium-chain 
triglycerides, olive oil and fish oil was found to be safe and well 
tolerated in children, and associated with a decreased bilirubin level, 
in one randomised controlled trial. The resolution of PN-associated 
jaundice was demonstrated in another study when patients switched 
from a soy bean-based emulsion to a mixed-lipid emulsion containing 
soy beans, medium-chain triglycerides, olive oil and fish oil.19,20 
Preventing energy and carbohydrate overload, and providing a 
taurine-containing amino acid solution and intermittent total PN in 
patients aged ≥ 3 months, are other nutritional strategies that can 
be used to prevent PNALD.7
Many aspects of the management of SBS in premature infants remain 
based on expert opinion because of the rarity of this syndrome and 
consequent lack of controlled trails. Future studies are needed to 
address some of the practical aspects of nutritional management, i.e. 
which type of enteral feed to use when breast milk is not available, 
in order to improve outcomes. The focus of nutritional management 
should be the facilitation of adequate growth, gut adaptation and 
fluid and electrolyte balance, as well as the prevention of long-term 
complications, i.e. PNALD. Management of these infants within a 
multidisciplinary team with expertise in the field of paediatric SBS 
should be prioritised.   
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